2019 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 60 pages | ID: 2BA637052F7EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Focal Segmental Glomerulosclerosis (FSGS). It presents in-depth analysis of Focal Segmental Glomerulosclerosis (FSGS) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Focal Segmental Glomerulosclerosis (FSGS).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Focal Segmental Glomerulosclerosis (FSGS) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Focal Segmental Glomerulosclerosis (FSGS)

The research work is prepared through extensive and continuous research on Focal Segmental Glomerulosclerosis (FSGS) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Focal Segmental Glomerulosclerosis (FSGS) patients are identified
• The report includes panorama of Focal Segmental Glomerulosclerosis (FSGS) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Focal Segmental Glomerulosclerosis (FSGS) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Region
  2.2.2 Average Enrollment of Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Focal Segmental Glomerulosclerosis (FSGS) Treatment, 2019

3. REGION WISE FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) CLINICAL TRIALS

3.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country
3.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country
3.3 North America Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country
3.4 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country
3.5 South and Central America Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country

4. FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) CLINICAL TRIAL TRENDS

4.1 Start Year wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials
4.2 Phase wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials
4.3 Trial Status wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials
4.4 Trial Type wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials

5. FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Year
5.2 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Phase
5.3 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Status
5.4 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) CLINICAL TRIALS

6.1 Focal Segmental Glomerulosclerosis (FSGS) Trials by Sponsor Type
6.2 Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase
7.2 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase
7.3 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase
7.4 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Figure 7: North America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Figure 9: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Phase
Figure 10: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Trial Status
Figure 11: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Type
Figure 12: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Sponsor Type
Figure 13: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Leading Sponsors
Figure 14: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Phase
Figure 15: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Trial Status
Figure 16: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Type
Figure 17: Focal Segmental Glomerulosclerosis (FSGS)- Average Enrolment by Type of Sponsors
Figure 18: Focal Segmental Glomerulosclerosis (FSGS)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Table 5: Europe – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Table 7: North America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Phase
Table 15: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Trial Status
Table 16: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Type
Table 17: Focal Segmental Glomerulosclerosis (FSGS)- Average Enrolment by Type of Sponsors
Table 18: Focal Segmental Glomerulosclerosis (FSGS)- Enrolment by Leading Sponsors